Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
OBJECTIVE
Clozapine and risperidone were the first two antipsychotic drugs of a new class of agents for the pharmacotherapy of schizophrenia. It has been suggested that refractory schizophrenic patients who fail to respond to neither clozapine nor risperidone may respond to a combination/augmentation strategy of both medicaments.


METHODS
Three cases of individuals with unremittent schizophrenia treated via this combination are presented. Response was evaluated by clinical follow-up and PANSS rating scale.


RESULTS
Good clinical results with no noticeable adverse side effects, ascertained by a reduction from baseline scores of the Positive and Negative Syndrome Scale (PANSS) were obtained in all three patients.


CONCLUSIONS
The findings from this pilot study suggest this combination as a possible therapeutic approach for treating resistant schizophrenic patients.
Raskin
S
S
The Kfar Shaul Mental Health Center, Jerusalem, Israel.
Katz
G
G
Zislin
Z
Z
Knobler
H Y
HY
Durst
R
R
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003024:Clozapine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index
D014150:Antipsychotic Agents; D003024:Clozapine; D018967:Risperidone